Westlake’s Kythera sells for $2.1 billion



An Irish-based company is buying Kythera Biopharmaceuticals (NASDAQ: KYTH) of Westlake Village in a $2.1-billion cash and stock transaction announced June 17. The deal allows Allergan (NYSE: AGN), a global pharmaceutical company headquartered in Dublin, to gain control of Kythera’s newly marketed treatment for reduction of the human double chin. Kythera’s Kybella injection is the first non-surgical treatment for double chins to receive FDA approval. Kythera is also seeking approval for the trea...

Thank you for supporting your local Acorn! You need to be a digital subscriber to view the rest of this content. Please Login or Subscribe Now!